<p>The management of non-muscle-invasive bladder cancer (NMIBC) has evolved from the first reports on bladder endoscopy and transurethral resection to the introduction of adjuvant intravesical treatment. However, disease recurrence and progression remain an ongoing risk, placing a heavy burden on healthcare resources and on patients’ quality of life. Deeper understanding of the molecular basis of the disease and developments in optics, lasers and computer science are already offering opportunities to revolutionize care and improve long-term prognosis. This article discusses developments likely to cause a paradigm shift towards the delivery of personalized care and reduced burden of disease in NMIBC.</p
This case-based discussion describes the clinical course of a 63-yr-old patient who presented with g...
Approximately 70% to 80% of patients with urothelial carcinomas of the bladder are initially diagnos...
Introduction: Nonmuscle invasive bladder cancer (NMIBC) is the most common presentation of bladder c...
The management of non-muscle-invasive bladder cancer (NMIBC) has evolved from the first reports on b...
Copyright © 2012 Daniel A. Barocas et al. This is an open access article distributed under the Creat...
Prof Per-Uno Malmström opened this symposium on non-muscle invasive bladder cancer (NMIBC) by descri...
Bladder cancer (BCa) is the most common malignancy of the urinary tract and one of the most prevalen...
Bladder cancer accounts for approximately 5-10% of all cancers in the United States and Europe and i...
International audienceWith 300,000 annually new cases worldwide, urothelial-cell carcinoma of the bl...
Introduction: Bladder cancer (BC) is a severe health burden: and has high recurrence and progression...
Bladder cancer is a highly prevalent disease associated with substantial morbidity, mortality and co...
Bladder cancer is a global health issue with sex differences in incidence and prognosis. Bladder can...
Bladder cancer is the second most common urological malignancy with a one in 28 lifetime risk. Three...
Non-muscle-invasive bladder cancer (NMIBC) is characterized by a high rate of cure, but also by a no...
Introduction: Management of high risk non-muscle invasive bladder cancer (NMIBC) is challenging. It ...
This case-based discussion describes the clinical course of a 63-yr-old patient who presented with g...
Approximately 70% to 80% of patients with urothelial carcinomas of the bladder are initially diagnos...
Introduction: Nonmuscle invasive bladder cancer (NMIBC) is the most common presentation of bladder c...
The management of non-muscle-invasive bladder cancer (NMIBC) has evolved from the first reports on b...
Copyright © 2012 Daniel A. Barocas et al. This is an open access article distributed under the Creat...
Prof Per-Uno Malmström opened this symposium on non-muscle invasive bladder cancer (NMIBC) by descri...
Bladder cancer (BCa) is the most common malignancy of the urinary tract and one of the most prevalen...
Bladder cancer accounts for approximately 5-10% of all cancers in the United States and Europe and i...
International audienceWith 300,000 annually new cases worldwide, urothelial-cell carcinoma of the bl...
Introduction: Bladder cancer (BC) is a severe health burden: and has high recurrence and progression...
Bladder cancer is a highly prevalent disease associated with substantial morbidity, mortality and co...
Bladder cancer is a global health issue with sex differences in incidence and prognosis. Bladder can...
Bladder cancer is the second most common urological malignancy with a one in 28 lifetime risk. Three...
Non-muscle-invasive bladder cancer (NMIBC) is characterized by a high rate of cure, but also by a no...
Introduction: Management of high risk non-muscle invasive bladder cancer (NMIBC) is challenging. It ...
This case-based discussion describes the clinical course of a 63-yr-old patient who presented with g...
Approximately 70% to 80% of patients with urothelial carcinomas of the bladder are initially diagnos...
Introduction: Nonmuscle invasive bladder cancer (NMIBC) is the most common presentation of bladder c...